Montis Biosciences BV of Belgium has appointed René Hoet, a molecular immunologist, as chief scientific officer to manage development of cancer therapeutics that target interactions between perivascular macrophages and the tumour vasculature. Dr Hoet was most recently CSO at Imcheck Therapeutics SAS in France where he helped build an antibody R&D group. Prior to Imcheck, he was vice president of biologics research at Bayer AG. Dr Hoet is also a professor of biopharmaceutics at the University of Maastricht in the Netherlands.
Montis Biosciences announced the appointment on 31 March 2021.
Copyright 2021 Evernow Publishing Ltd